

# Molecular pathogenesis of pediatric thyroid carcinoma

Norisato Mitsutake<sup>1,2,\*</sup> and Vladimir Saenko<sup>2</sup>

<sup>1</sup>Department of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

<sup>2</sup>Radiation Molecular Epidemiology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

\*Corresponding author. Department of Radiation Medical Sciences and Radiation Molecular Epidemiology, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. Tel: 095-819-7116; Fax: 095-819-7117; Email: mitsu@nagasaki-u.ac.jp

(Received 18 August 2020; revised 16 September 2020; editorial decision 23 September 2020)

## ABSTRACT

There has been little understanding of the molecular pathogenesis of pediatric thyroid cancers. Most of them are histologically classified as papillary thyroid carcinoma (PTC). Ionizing radiation is the most important environmental factor to induce PTC, especially in children. Particularly, radiation-related pediatric PTCs after the Chernobyl accident provided invaluable information. In addition, the recent accumulation of sporadic pediatric PTC cases, partly due to advances in diagnostic imaging, has also provided insight into their general pathogenesis. In PTC development, basically two types of genetic alterations, fusion oncogenes, mainly *RET/PTC*, and a point mutation, mainly *BRAF*<sup>V600E</sup>, are thought to play a key role as driver oncogenes. Their frequencies vary depending on patient age. The younger the age, the more prevalent the fusion oncogenes are. Higher incidence of fusion oncogenes was also observed in cases exposed to radiation. In short, fusion oncogenes are associated with both age and radiation and are not evidence of radiation exposure. The type of driver oncogene is shifted toward *BRAF*<sup>V600E</sup> during adolescence in sporadic PTCs. However, until about this age, fusion oncogenes seem to still confer dominant growth advantages, which may lead to the higher discovery rate of the fusion oncogenes. It has been postulated that *RET/PTC* in radiation-induced PTC is generated by ionizing radiation; however, there is an interesting hypothesis that thyroid follicular cell clones with pre-existing *RET/PTC* were already present, and radiation may play a role as a promoter/progressor but not initiator. Telomerase reverse transcriptase gene (*TERT*) promoter mutations, which are the strongest marker of tumor aggressiveness in adult PTC cases, have not been detected in pediatric cases; however, *TERT* expression without the mutations may play a role in tumor aggressiveness. In this paper, the recent information regarding molecular findings in sporadic and radiation-associated pediatric PTCs is summarized.

## INTRODUCTION

Thyroid cancer is the most frequent malignant tumor in the endocrine system. Its incidence is increasing worldwide and was 14.3 per 100 000 people in 2017 in Japan [Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Ministry of Health, Labour and Welfare, National Cancer Registry)]. Thyroid cancer in the young population is rare, and its incidence rates (per 100 000) in 2015 in Japan are estimated to be 0.039 (boys) and 0 (girls) for ages 0–4, 0.110 (boys) and 0.385 (girls) for ages 5–9, 0.417 (boys) and 0.547 (girls) for ages 10–14, and 0.771 (boys) and 2.787 (girls) for ages 15–19, in total 1.353 under 19 years old [Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan (Monitoring of Cancer Incidence in Japan)]. Histologically, thyroid cancer is classified into papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma

(MTC). PTC and FTC are sometimes referred to as differentiated thyroid carcinoma (DTC). The only exception regarding originating cells is MTC, which is derived from parafollicular C cells, while the others are from thyroid follicular cells. The majority of cases are PTCs, accounting for ~90% in Japan.

Ionizing radiation is well known to induce thyroid cancer, and the histological type of radiation-induced thyroid cancer is also PTC. Children are far more susceptible to ionizing radiation, the risk sharply decreased with increasing age-at-exposure, and at >20 years old there was little increase in risk [1, 2]. Therefore, this review focuses on molecular pathogenesis of PTC, especially among pediatric and adolescent cases.

## DRIVER ONCOGENES

First, we describe driver oncogenes that are thought to play a major role in carcinogenesis of PTC. Regardless of age of onset, PTC has a

particular series of driver oncogenes leading to the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which is implicated in cell growth and dedifferentiation [3]. The major ones are: the *BRAF*<sup>V600E</sup> mutation and *RET/PTC* and *ETV6/NTRK3* fusion genes, and these account cumulatively for >90% in Japan.

*BRAF* is a serine/threonine kinase and a member of the MAPK pathway and transmits a signal from RAS to MEK. Most of the *BRAF* mutations found in PTCs are *BRAF*<sup>V600E</sup>. The V600E mutation is a thymine-to-adenine transversion at nucleotide 1799, resulting in a valine-to-glutamic acid substitution at codon 600 (p.V600E), which converts the kinase into a constitutively active form without stimulus form RAS. This *BRAF*<sup>V600E</sup> mutation is the most prevalent genetic change in adult PTCs. Its prevalence seems to be dependent on regions: generally lower (40–60%) in Western countries and higher (60–80%) in Asian countries including Japan [4]. It has been reported that this mutation frequency is associated with the amount of iodine intake [5], but this is still controversial [6], and its cause remains unclear. It also should be noted that regarding the pathological diagnosis of PTC, there is considerable inter-observer variation, even among thyroid pathology experts, especially when they work in different countries [7]. Pathologists in the USA tend to diagnose a tumor with slight papillary nuclear features as a PTC, and such a tumor may be diagnosed as a benign follicular adenoma (FA) in Japan. This difference probably affects the mutation frequency described above. Another important difference among different regions is the association between the *BRAF*<sup>V600E</sup> mutation and clinicopathological aggressiveness. In Western countries, there are many reports demonstrating that PTCs harboring this mutation show higher frequencies of extrathyroidal extension, recurrence and advanced stages [8]. On the other hand, most reports from Japan suggest no such correlations [9–11]. The reason for this difference is also unknown.

*RET* is a transmembrane receptor tyrosine kinase and is usually not expressed in thyroid follicular cells. However, by chromosomal rearrangement, the C-terminal kinase domain of *RET* is fused to the N-terminal domain of a partner gene, and its promoter drives transcription of the fusion gene, which is called *RET/PTC* when this fusion is found in PTC [12]. So far, at least 19 different types of *RET/PTC* chimeric genes that differ according to partner genes have been identified [13]. *RET/PTC1* and *RET/PTC3* are the most common types, both of which are generated by intrachromosomal inversion in chromosome 10, and account for >90% of all *RET/PTCs*. The N-terminal domain from the partner genes usually has a portion promoting dimerization, such as the coiled-coil domain, leading to dimerization and autophosphorylation of key tyrosine residues located in the *RET* kinase domain in a ligand-independent manner, then resulting in constitutive activation of the kinase. The frequency of *RET/PTCs* in adult sporadic PTCs is ~5–15% [12, 14].

The *ETV6/NTRK3* fusion also has a similar activation mechanism, between the *ETV6* gene on chromosome 12 and the *NTRK3* gene on chromosome 15. *NTRK3* is also a transmembrane receptor tyrosine kinase that is involved in neuronal cellular processes. The N-terminal of *ETV6* has the SAM domain, promoting dimerization and resulting in constitutive activation of the kinase function of *NTRK3* as well. The frequency of this fusion in adult sporadic PTCs is usually a few percent [14–16].

As described above, RAS is also a member of the MAPK signaling pathway; however, in thyroid follicular cells, mutant RAS seems to

preferentially activate the PI3K-AKT pathway rather than the MAPK pathway. The activation of the PI3K-AKT pathway generally drives development of another type of DTC, FTC. Therefore, the RAS mutations are frequently detected in FTC and also in FA, albeit with lower prevalence [3]. The frequency of the RAS mutations in PTC is very low, up to a few percent in Japan (N. Mitsutake and V. Saenko, unpublished results), mainly in a follicular variant of PTC. However, its frequency in PTC in the USA is 10–15% [14], presumably because of the inter-observer variation described above. RAS consists of three isoforms: *KRAS*, *NRAS* and *HRAS*, and the most prevalent mutation in thyroid carcinoma is *NRAS* at codon 61. Mutations in RAS render RAS proteins insensitive to GTPase-activating proteins, leading to constitutive activation of RAS.

These driver oncogenes are mutually exclusive [14, 17]. Since *RET* and *NTRK3* activate not only the MAPK signaling pathway but also PI3K and PLC $\gamma$  [18, 19], this mutually exclusive event provides strong genetic evidence that the activation of the MAPK pathway is a key to development of PTC. The difference between the receptor tyrosine kinase fusion genes and *BRAF*<sup>V600E</sup> is the magnitude of output of the MAPK signaling. This is due to insensitivity of the mutant *BRAF* to negative feedback of the MAPK pathway, and the mutant *BRAF* leads to more elevated expression of ETS/MYC/FOS compared with receptor tyrosine kinases [20]. It is assumed that this difference may be one of the reasons that tumors with *BRAF*<sup>V600E</sup> are more aggressive, although this is not the case in Japan. The activation of the MAPK pathway is also associated with dedifferentiation, and impairment of iodine metabolism causes resistance to radioiodine therapy [18, 21, 22].

The frequency of the above oncogenes, especially *BRAF*<sup>V600E</sup> and *RET/PTC*, apparently varies with patient age. As described above, in adult PTCs, the *BRAF*<sup>V600E</sup> mutation is the most prevalent, accounting for 50–85%. On the other hand, in pediatric sporadic PTCs, it has been reported to be 0–63%, although the numbers of analyzed cases were limited in most of the studies [23, 24]. Regarding *RET/PTC*, the opposite trend is observed. In adult sporadic PTCs, its frequency is generally 5–15%, while in pediatric cases, it is 25–65% [24].


Recent improvement in detection methods, including sharing information regarding primers/probes, may change sensitivity/specificity of detection of the oncogenes. Hence, recent papers (in the last 5 years) reporting the prevalence of the oncogenes, especially *BRAF*<sup>V600E</sup> and/or *RET/PTC* in pediatric PTCs, are summarized in Table 1 and Fig. 1 [25–39]. Their overall frequencies in the 15 publications are: *BRAF*<sup>V600E</sup>, 28.4% and *RET/PTC*, 24.6%, while they were 13 and 41%, respectively, in the previous review published in 2015 [24]. In terms of the *BRAF*<sup>V600E</sup> mutation, its frequency still seems to be lower than that in adult cases analyzed at the same time in three studies (Fig. 1). There is an impression that the data in recent years have been a bit closer to that of adult PTCs. This trend might be due to the recent spread and advances of ultrasound imaging systems, and small and slow-growing tumors may be detected earlier. However, there is no clear explanation so far.

## TERT PROMOTER MUTATION

Recently, point mutations in the promoter region of the telomerase reverse transcriptase gene (*TERT*) have been found in many types of cancers including PTCs [40–42]. There are two recurrent

**Table 1. Recent publications demonstrating the prevalence of major oncogenes in pediatric PTCs**

PMID	Year	Author	Country	No. of PTCs	Age <sup>a</sup>	BRAF	RET/PTC	ETV6/NTRK3	Reference
32495721	2020	Pekova	Czech	93	14.5 (6–20)	18 (19.4%)	19 (20.4%)	10 (10.8%)	39
31456750	2019	Galuppini	Italy	54	14.4 (6.4–17.8)	8/50 (16.0%)	14 (25.9%)		38
30924609	2019	Sisdelli	Brazil	80	12.7 (3–18)	12 (15.0%)			37
28646474	2017	Geng	China	48	(3–13)	16 (35.4%)			36
28521635	2017	Hardee	USA	59		24/50 (48.0%)			35
28209747	2017	Vanden Borre	USA	12	12.8 (7–19)	2 (16.7%)	4 (33.3%)		34
28176151	2017	Oishi	Japan	81	17.4 (6–20)	44 (54.3%)			33
28077340	2017	Poyrazoglu	Turkey	75	12.4 (1.3–17.8)	14/56 (25.0%)			32
27849443	2017	Cordioli	Brazil	35	11.8 (4–18)	3 (8.6%)	14 (40.0%)	3 (8.6%)	31
27824297	2017	Alzahrani	Saudi Arabia	72	15.5 <sup>b</sup> (8–18)	19 (26.4%)			30
26951110	2016	Onder	Turkey	50	14.7 (6–18)	15 (30.0%)			29
26910217	2016	Gertz	USA	13	13	4 (30.8%)			28
26784937	2016	Prasad	USA	28	(6–18)	13 (46.4%)	6 (21.4%)	5 (17.9%)	27
26711586	2016	Alzahrani	Saudi Arabia	53	16 <sup>b</sup> (9–18)	12 (22.6%)			26
26649796	2016	Nikita	USA	28	14.7 (7.9–18.4)	9 (32.1%)	6 (17.6%)		25

<sup>a</sup>Mean (range);<sup>b</sup>median.

**Fig. 1. The frequencies of  $BRAF^{V600E}$  (left) and  $RET/PTCs$  (right) in sporadic pediatric PTC cases in 15 papers published after 2016. Three studies also examined the prevalence of  $BRAF^{V600E}$  in adult cases simultaneously (middle); same studies are connected by lines. Total numbers and percentages of each oncogene are also shown below.**

locations, called C228T (derived from chromosomal location, chr5: 1 295 228C > T) and C250T (chr5: 1 295 250C > T). They are mutually exclusive, and C228T is more frequent in PTCs [42]. The prevalence of either mutation in adult sporadic PTCs is ~10%. These mutations create a binding site for the ETS family transcription factors [43, 44]. When the ETS family members are activated (e.g. by  $BRAF^{V600E}$ ),  $TERT$  transcription is further upregulated. Indeed, the coexistence of both the  $TERT$  promoter mutation and the  $BRAF^{V600E}$  mutation has a strong negative impact on PTC aggressiveness and prognosis [42]. Unlike the  $BRAF^{V600E}$  mutation, no regional differences have been recognized in this correlation so far. Another important link

between these mutations and clinical parameter is age dependence. These mutations are rarely detected in cases <45 years old. According to our data of Japanese PTC patients, its frequency increases with age, and in cases >70 years old, about half of the cases carry this mutation [10].

Very recently, it has been found that there are some PTC cases that show  $TERT$  mRNA expression even in the absence of the  $TERT$  promoter mutations [11]. If cases with very small amount of expression are included, nearly 40% of the mutation-negative cases are positive for  $TERT$  expression. Interestingly, high  $TERT$  expression has been reported to be associated with worse prognosis as well. Unlike the  $TERT$  promoter mutations, the tumors with high  $TERT$  expression are found among relatively younger cases, implying that  $TERT$  expression may be a good molecular marker to predict disease outcome in young cases. We detected  $TERT$  expression in cases <20 years old but the number of analyzed cases was very limited, and further study is needed.

#### CHERNOBYL RADIATION-INDUCED PTC

After the accident at the Chernobyl nuclear power plant in 1986, a dramatic increase in the incidence of childhood thyroid cancer was observed, starting from around 1990. This was due to exposure to radioiodine ( $^{131}I$ ) released from the reactor. Since the half-life of  $^{131}I$  is ~8 days, the children born after the accident were virtually unaffected [45]. The higher incidence was observed in children of younger ages, particularly <5 five years old at the time of the accident [46]. Therefore, they were basically childhood PTCs. However, since, once exposed, the elevated risk of cancer development may continue for their lifetime, there may be radiation-induced adult PTC cases these days, although it is difficult to distinguish them from sporadic cases.

Regarding driver oncogenes, in cases with short latency (<7–10 years after the accident), a very high rate of  $RET/PTC$  (65–86%) and no  $BRAF^{V600E}$  mutations were observed [47]. In cases with long latency (>9–10 years after the accident), the frequencies of  $RET/PTC$  and the  $BRAF^{V600E}$  mutation were 50–60% and 4–16%, respectively [47], which is not much different from those of pediatric sporadic PTC cases [24]. The cases that were exposed after birth and developed PTC ~5 years after the exposure, which were certainly radiogenic, were

very young, which is almost never seen in sporadic PTCs. Therefore, it is still not clear and controversial whether this genetic pattern (the very high rate of *RET/PTC* and no *BRAF<sup>V600E</sup>*) is due to radiation exposure or just age of onset. Powell *et al.* examined the presence of *RET/PTC* and *BRAF<sup>V600E</sup>* in 27 exposed cases (median age 13.8 years, range 10.3–15.7) and 8 unexposed cases (median age 11.9 years, range 7.9–15.1) from Ukraine, and found no difference in the frequency of both oncogenes [48]. On the other hand, Ricarte-Filho *et al.* examined 26 radiation-associated PTCs from Ukraine and 27 age-matched sporadic PTCs from the same regions and compared their pattern of oncogenes [49]. Although their median ages of the radiation and sporadic groups were 17.8 and 16.6 years, respectively, fusion oncogenes including *RET/PTC* were significantly more prevalent in the radiation-exposed cases (84.6%) compared with the sporadic cases (33.3%). Another study by Efanov *et al.* has demonstrated an association between radiation dose and the prevalence of fusion oncogenes in 65 Ukrainian cases [50]. The mean <sup>131</sup>I dose in cases with fusion oncogenes was significantly higher than that in point mutation-positive cases. Even in multivariate analysis, the adjusted odds ratio for cases with fusion oncogenes relative to cases with point mutations still significantly increased with <sup>131</sup>I dose. The latter two studies investigated not only *RET/PTC1* and 3, which are the most prevalent fusion oncogenes in PTCs, but also other fusion oncogenes such as relatively rare *RET/PTCs* and other fusions with *NTRK* and *BRAF*. These indicate that the frequency of fusion oncogenes may be affected by both radiation exposure and younger age. It should also be noted that the radiation-exposed cases described above may contain actual sporadic cases. So far, there is no specific genetic alteration that is exclusive to radiation-induced PTC.

### FUKUSHIMA PEDIATRIC AND ADOLESCENT THYROID CANCERS

After the accident at the Fukushima Daiichi Nuclear Power Plant in March 2011, a large amount of radioiodine was released into the environment. Although estimated thyroid doses in Fukushima were very low, a thyroid ultrasound screening program for all children aged 0–18 years old at the time of the accident was started in October 2011. In the first round of the screening, the so-called baseline survey, ~100 thyroid cancers per 300 000 children were found. These cancers were not thought to be radiogenic because of low thyroid doses and too short latency.

Among these, we investigated the driver oncogenes in 63 PTC cases (mean age at operation: 17.7 years) [51]. We detected *BRAF<sup>V600E</sup>* in 43 cases (68.3%), *RET/PTC* in 7 (11.1%) and *ETV6/NTRK3* in 4 (6.3%). The *TERT* promoter mutations were not found. The frequencies of *BRAF<sup>V600E</sup>* and *RET/PTC* were the highest and the lowest, respectively, compared with previous reports regarding pediatric PTCs. This oncogenic profile is similar to adult sporadic cases. Note that almost all of these tumors were asymptomatic and discovered by the mass screening. Therefore, if they had not been screened, they would be latent until a later age. This logically explains why they had the oncogenic profile described.

Another interesting finding in this study is that tumors with the *BRAF<sup>V600E</sup>* mutation were significantly smaller in size than those without this mutation, most of which presumably harbor fusion genes [51]. This implies that in this age group, the *BRAF<sup>V600E</sup>* mutation does not

confer a dominant growth advantage on PTC compared with other fusion oncogenes. On the other hand, it may be considered that tumors with fusion oncogenes are more aggressive. As described earlier, there are many publications demonstrating that tumors with the *BRAF<sup>V600E</sup>* mutation display more aggressive clinicopathological features in adult sporadic PTCs, and this is the opposite result. Again, note that this aggressiveness is absent in Japanese cases. This finding also supports the above oncogenic profile. Without screening, only children having a symptom due to a large tumor visit a hospital, and such tumors have a fusion oncogene. Therefore, in previous reports about pediatric PTCs, fusion oncogenes, including *RET/PTC*, were more prevalent than *BRAF<sup>V600E</sup>* [24]. In recent years, there are some consistent data. Pekova *et al.* have demonstrated that fusion-positive PTCs were significantly associated with extrathyroidal extension, higher T status, and distant metastasis compared with fusion-negative PTCs [39]. Geng *et al.* have also reported that the presence of the *BRAF<sup>V600E</sup>* mutation was associated with lower risk scores (MACIS/AMES) and concluded that the mutation negatively correlated with aggressiveness of pediatric PTCs [36]. However, Onder *et al.* have shown adverse correlation between the *BRAF<sup>V600E</sup>* mutation and disease-free survival, although this correlation was mainly due to histological variants [29]. These findings suggest that different types of driver oncogenes (*BRAF<sup>V600E</sup>* or fusion oncogenes) may have different roles compared with those in adult cases (Table 2).

### A HYPOTHESIS OF PRE-EXISTING FUSION ONCOGENES

It has been thought that *RET/PTC* in radiation-induced pediatric PTCs around Chernobyl are generated by ionizing radiation because two breakpoints involved in generation of *RET/PTC* are physically close in the nucleus of interphase human thyroid cells (but not other type of cells) and also have sequence homology [52, 53]. Therefore, it may be possible that a single radiation track can produce two double strand breaks and generate *RET/PTC*. In addition, radiation exposure to normal human thyroid cells produced *RET/PTC in vitro* in a dose-dependent manner [54], albeit at very high dose. However, the latent period of the first childhood PTC cases that developed in ~1990, which were most likely radiogenic, was very short, which means that it took only 4 or 5 years since the first hit (initiation) in a single cell.

Nakamura proposed an interesting hypothesis regarding radiation-related leukemia [55]. Generation of fusion genes specific to acute lymphocytic leukemia (ALL) occurs much more frequently than actual ALL cases. In addition, clonal expansion of the cells harboring the fusion gene is often found in individuals who do not develop ALL. Hence, it was postulated that the risk for radiation-induced ALL may be attributable to a small number of individuals who already had the clone that expanded to a certain size.

There is no such evidence for fusion oncogenes in PTCs such as *RET/PTC*; however, *RET/PTC* was reported to be present in benign adenomas and also in Hashimoto thyroiditis tissues [12, 56], although these findings still remain controversial. Some of the above studies might have detected *RET/PTC* in normal untransformed cells. Assuming that there already were thyroid follicular cells with *RET/PTC*, radiation may play a role as a promoter/progressor, not initiator, enabling short latency within 4–5 years. However, this is just a hypothesis, and further study is definitely necessary.

**Table 2. Current hypothesis on crucial driver oncogenes in different etiologies and age groups**

Age at diagnosis		Radiation-induced (Chernobyl)	Sporadic
5–10 years (Pediatric)	Initiating event frequency	Fusion	Very rare
	Importance in growth advantage	Fusion	
10–20 years (Adolescent)	Initiating event frequency	Fusion $\gg$ BRAF	Fusion < BRAF <sup>a</sup>
	Importance in growth advantage	Fusion $\gg$ BRAF	Fusion $\gg$ BRAF
20+ years (adult)	Initiating event frequency	Fusion > ? BRAF	Fusion $\ll$ BRAF
	Importance in growth advantage	Fusion ? BRAF	Fusion < ? BRAF

<sup>a</sup>Including latent cases.

?: still not clear

### CONCLUSION

In PTCs, the major difference in molecular pathogenesis between childhood and adult cases lies in the difference between fusion genes and point mutations, mainly  $BRAF^{V600E}$ , as a driver oncogene. The younger the age, the more important the fusion oncogenes are in the development of PTC. In teenagers or older cases, it is assumed that  $BRAF^{V600E}$  becomes a major player if latent cases are included. Regarding aggressiveness, in childhood and adolescent PTCs, fusion oncogenes may have a higher growth impact compared with  $BRAF^{V600E}$ , although this is not the case in adult PTCs. In radiation-associated PTCs, the frequency of fusion oncogenes is certainly high. However, the frequency itself depends on both radiation exposure and younger age. It is apparent that radiation increases the risk for PTC development in children; however, its molecular mechanisms including how fusion genes are generated still remain to be elucidated.

### SUPPLEMENT FUNDING

This work was supported by the Program of the Network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University.

### CONFLICT OF INTEREST

None declared.

### REFERENCES

- Ron, E, Lubin, JH, Shore, RE et al. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. *Radiat Res.* 1995; 141(3): 259–77.
- Furukawa, K, Preston, D, Funamoto, S et al. Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. *Int J Cancer.* 2013; 132(5): 1222–6.
- Kondo, T, Ezzat, S, Asa, SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. *Nat Rev Cancer.* 2006; 6(4): 292–306.
- Song, YS, Lim, JA, Park, YJ. Mutation profile of well-differentiated thyroid cancer in Asians. *Endocrinol Metab (Seoul).* 2015; 30(3): 252–62.
- Guan, H, Ji, M, Bao, R et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. *J Clin Endocrinol Metab.* 2009; 94(5): 1612–7.
- Vuong, HG, Kondo, T, Oishi, N et al. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. *Cancer Med.* 2016; 5(8): 1883–9.
- Elsheikh, TM, Asa, SL, Chan, JK et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. *Am J Clin Pathol.* 2008; 130(5): 736–44.
- Xing, M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. *Endocr Rev.* 2007; 28(7): 742–62.
- Ito, Y, Yoshida, H, Maruo, R et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: Its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. *Endocr J.* 2009; 56(1): 89–97.
- Matsuse M, Yabuta T, Saenko V et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: Combination of two independent factors. *Sci Rep.* 2017;7:41752.
- Tanaka, A, Matsuse, M, Saenko, V et al. TERT mRNA expression as a novel prognostic marker in papillary thyroid carcinomas. *Thyroid.* 2019; 29(8): 1105–14.
- Nikiforov, YE. RET/PTC rearrangement in thyroid tumors. *Endocr Pathol.* 2002; 13(1): 3–16.
- Yakushina, VD, Lerner, LV, Lavrov, AV. Gene fusions in thyroid cancer. *Thyroid.* 2018; 28(2): 158–67.
- Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. *Cell.* 2014; 159(3): 676–90.
- Leeman-Neill, RJ, Kelly, LM, Liu, P et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. *Cancer.* 2014; 120(6): 799–807.
- Bastos, AU, de Jesus, AC, Recutti, JM. ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population. *Eur J Endocrinol.* 2018; 178(1): 83–91.
- Kimura, ET, Nikiforova, MN, Zhu, Z et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res.* 2003; 63(7): 1454–7.
- Knauf, JA, Kuroda, H, Basu, S et al. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. *Oncogene.* 2003; 22(28): 4406–12.

19. Lange, AM, Lo, HW. Inhibiting TRK proteins in clinical cancer therapy. *Cancers (Basel)*. 2018; 10(4).
20. Pratilas, CA, Taylor, BS, Ye, Q et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc Natl Acad Sci U S A*. 2009; 106(11): 4519–24.
21. Mitsutake, N, Knauf, JA, Mitsutake, S et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. *Cancer Res*. 2005; 65(6): 2465–73.
22. Caronia, LM, Phay, JE, Shah, MH. Role of BRAF in thyroid oncogenesis. *Clin Cancer Res*. 2011; 17(24): 7511–7.
23. Henke, LE, Perkins, SM, Pfeifer, JD et al. BRAF V600E mutational status in pediatric thyroid cancer. *Pediatr Blood Cancer*. 2014; 61(7): 1168–72.
24. Cordioli, MI, Moraes, L, Cury, AN et al. Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma? *Endocr Relat Cancer*. 2015; 22(6): R311–24.
25. Nikita, ME, Jiang, W, Cheng, SM et al. Mutational analysis in Pediatric thyroid cancer and correlations with age, ethnicity, and clinical presentation. *Thyroid*. 2016; 26(2): 227–34.
26. Alzahrani, AS, Qasem, E, Murugan, AK et al. Uncommon TERT promoter mutations in Pediatric thyroid cancer. *Thyroid*. 2016; 26(2): 235–41.
27. Prasad, ML, Vyas, M, Horne, MJ et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in Northeast United States. *Cancer*. 2016; 122(7): 1097–107.
28. Gertz, RJ, Nikiforov, Y, Rehrauer, W et al. Mutation in BRAF and other members of the MAPK pathway in papillary thyroid carcinoma in the Pediatric population. *Arch Pathol Lab Med*. 2016; 140(2): 134–9.
29. Onder, S, Ozturk Sari, S, Yegen, G et al. Classic architecture with multicentricity and local recurrence, and absence of TERT promoter mutations are correlates of BRAF (V600E) Harboring Pediatric papillary thyroid carcinomas. *Endocr Pathol*. 2016; 27(2): 153–61.
30. Alzahrani, AS, Murugan, AK, Qasem, E et al. Single point mutations in Pediatric differentiated thyroid cancer. *Thyroid*. 2017; 27(2): 189–96.
31. Cordioli, MI, Moraes, L, Bastos, AU et al. Fusion oncogenes are the main genetic events found in sporadic papillary thyroid carcinomas from children. *Thyroid*. 2017; 27(2): 182–8.
32. Poyrazoglu, S, Bundak, R, Bas, F et al. Clinicopathological characteristics of papillary thyroid cancer in children with emphasis on pubertal status and association with BRAF(V600E) mutation. *J Clin Res Pediatr Endocrinol*. 2017; 9(3): 185–93.
33. Oishi, N, Kondo, T, Nakazawa, T et al. Frequent BRAF (V600E) and absence of TERT promoter mutations characterize sporadic Pediatric papillary thyroid carcinomas in Japan. *Endocr Pathol*. 2017; 28(2): 103–11.
34. Vanden Borre, P, Schrock, AB, Anderson, PM et al. Pediatric, adolescent, and young adult thyroid carcinoma Harbors frequent and diverse targetable genomic alterations, including kinase fusions. *Oncologist*. 2017; 22(3): 255–63.
35. Hardee, S, Prasad, ML, Hui, P et al. Pathologic characteristics, natural history, and prognostic implications of BRAF(V600E) mutation in Pediatric papillary thyroid carcinoma. *Pediatr Dev Pathol*. 2017; 20(3): 206–12.
36. Geng, J, Wang, H, Liu, Y et al. Correlation between BRAF (V600E) mutation and clinicopathological features in pediatric papillary thyroid carcinoma. *Sci China Life Sci*. 2017; 60(7): 729–38.
37. Sisdelli, L, Cordioli, M, Vaisman, F et al. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. *Pediatr Blood Cancer*. 2019; 66(7): e27707.
38. Galuppini F, Vianello F, Censi S et al. Differentiated thyroid carcinoma in Pediatric age: Genetic and clinical scenario. *Front Endocrinol (Lausanne)*. 2019;10:552.
39. Pekova B, Sykorova V, Dvorakova S et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of Pediatric papillary thyroid carcinomas. *Thyroid*. 2020.
40. Landa, I, Ganly, I, Chan, TA et al. Frequent somatic TERT promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. *J Clin Endocrinol Metab*. 2013; 98(9): E1562–6.
41. Vinagre J, Almeida A, Populo H et al. Frequency of TERT promoter mutations in human cancers. *Nat Commun*. 2013;4:2185.
42. Liu, R, Xing, M. TERT promoter mutations in thyroid cancer. *Endocr Relat Cancer*. 2016; 23(3): R143–55.
43. Huang, FW, Hodis, E, Xu, MJ et al. Highly recurrent TERT promoter mutations in human melanoma. *Science*. 2013; 339(6122): 957–9.
44. Lin, HY, Chin, CY, Huang, HL et al. Crystalline inorganic frameworks with 56-ring, 64-ring, and 72-ring channels. *Science*. 2013; 339(6121): 811–3.
45. Shibata, Y, Yamashita, S, Masyakin, VB et al. 15 years after Chernobyl: New evidence of thyroid cancer. *Lancet*. 2001; 358(9297): 1965–6.
46. Ron, E. Thyroid cancer incidence among people living in areas contaminated by radiation from the Chernobyl accident. *Health Phys*. 2007; 93(5): 502–11.
47. Nikiforov, YE. Radiation-induced thyroid cancer: What we have learned from Chernobyl. *Endocr Pathol*. 2006; 17(4): 307–17.
48. Powell, N, Jeremiah, S, Morishita, M et al. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. *J Pathol*. 2005; 205(5): 558–64.
49. Ricarte-Filho, JC, Li, S, Garcia-Rendueles, ME et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. *J Clin Invest*. 2013; 123(11): 4935–44.
50. Efanov, AA, Brenner, AV, Bogdanova, TI et al. Investigation of the relationship between radiation dose and gene mutations and fusions in post-Chernobyl thyroid cancer. *J Natl Cancer Inst*. 2018; 110(4): 371–8.
51. Mitsutake N, Fukushima T, Matsuse M et al. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: A different oncogenic profile from Chernobyl. *Sci Rep*. 2015;5:16976.
52. Nikiforov, YE, Koshoffer, A, Nikiforova, M et al. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in

- radiation-induced thyroid carcinomas. *Oncogene*. 1999; 18(46): 6330–4.
53. Nikiforova, MN, Stringer, JR, Blough, R et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. *Science*. 2000; 290(5489): 138–41.
54. Caudill, CM, Zhu, Z, Ciampi, R et al. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation. *J Clin Endocrinol Metab*. 2005; 90(4): 2364–9.
55. Nakamura, N. A hypothesis: Radiation-related leukemia is mainly attributable to the small number of people who carry pre-existing clonally expanded preleukemic cells. *Radiat Res*. 2005; 163(3): 258–65.
56. Sadetzki, S, Calderon-Margalit, R, Modan, B et al. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. *J Clin Endocrinol Metab*. 2004; 89(5): 2281–9.